Cell and Immune Therapy Technologies
Gamida Cell Ltd. is a leader in immuno oncology. The company develops treatments for orphan hematological diseases and malignancies using stem cells and NK cells.
The company’s lead product is NiCord®. It is currently being researched in a Phase I/II clinical study as an experimental treatment for blood cancers such as leukemia and lymphoma. Following positive feedback of the phase III study outline from the FDA and EMA, Gamida Cell plans to begin a Phase III trial of NiCord in Q3/2016. Click here to learn more about NiCord.
Also in the pipeline: CordIn™ and an NK Cell Product:
CordIn™is in development as an experimental treatment for a variety of diseases. CordIn is being studied in a Phase I/II clinical trial for patients with sickle cell disease or thalassemia. A Phase I/II study of CordIn as a treatment for aplastic anemia is scheduled to commence in 2016. Click here to learn more about CordIn.
Gamida Cell’s NK cell product is an experimental immune therapy for the treatment of blood cancers refractory to chemotherapy. Two Phase I/II clinical trials are planned to begin in early 2016. Click here to learn more about the NK cell product.